In a 'Vant' first, urology drug looks like a winner  

One star in the "Vant" constellation of companies is suddenly shining brighter. Urovant, the urology spinout from hedge fund manager turned biotech entrepreneur Vivek Ramaswamy, said its overactive-bladder drug hit all its goals in a late-stage trial.

That’s a remarkable turn of events, five years after a spectacular Alzheimer’s drug blowup from Axovant, STAT’s Adam Feuerstein reports. And although Urovant’s lead pipeline drug, vibregon, treats a less common and arguably less challenging condition, there is money to be made: Myrbetriq, marketed by Astellas, hauled in $750 million in sales last year.

Next up for Urovant: revealing more details at a medical meeting, gaining FDA approval, and convincing insurers not to go with a cheaper generic.

Read more.